542 Results for "

Myeloma

" in MedChemExpress (MCE) Product Catalog:
Products (542)

542 Results for "Myeloma" in MCE Product Catalog:

271
271 Publications Verification
Cat. No.: HY-10227
CAS No.: 179324-69-7
Purity:  99.91%
Synonyms: PS-341; LDP-341; NSC 681239
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
loading...
    loading...
111
111 Cited Publications
Cat. No.: HY-10046
CAS No.: 110078-46-1
Purity:  99.90%
Synonyms: AMD 3100; JM3100; SID791
Target:  

CXCR HIV

Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
loading...
    loading...
89
89 Cited Publications
Cat. No.: HY-10224A
CAS No.: 960055-56-5
Purity:  98.67%
Synonyms: LBH589 lactate; NVP-LBH589 lactate
Target:  

HDAC HIV Autophagy Apoptosis

Research Areas:  

Infection Cancer

Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
89
89 Cited Publications
Cat. No.: HY-10224
CAS No.: 404950-80-7
Purity:  99.37%
Synonyms: LBH589; NVP-LBH589
Target:  

HDAC Autophagy HIV Apoptosis

Research Areas:  

Cancer

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
75
75 Cited Publications
Cat. No.: HY-10971
CAS No.: 1028486-01-2
Purity:  99.36%
Synonyms: MLN 8237
Research Areas:  

Cancer

Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50876
CAS No.: 658084-64-1
Synonyms: FK866; APO866
Research Areas:  

Cancer

Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-A0003
CAS No.: 191732-72-6
Synonyms: CC-5013
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-A0003B
CAS No.: 847871-99-2
Synonyms: CC-5013 hemihydrate
Research Areas:  

Cancer

Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-12861
CAS No.: 1542705-92-9
Purity:  99.90%
Target:  

p97

Research Areas:  

Cancer

CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase/VCP. CB-5083 selectively inhibits p97 through its D2 site with the IC50 of 11 nM .
loading...
    loading...
45
45 Cited Publications
Cat. No.: HY-N0176
CAS No.: 71939-50-9
Synonyms: Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol
Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-15473A
CAS No.: 1782573-78-7
Purity:  99.73%
Synonyms: ML120B dihydrochloride
Target:  

IKK

Research Areas:  

Inflammation/Immunology Cancer

MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-15473
CAS No.: 783348-36-7
Purity:  99.76%
Synonyms: ML120B
Target:  

IKK

Research Areas:  

Cancer

MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-13032B
CAS No.: 1895049-20-3
Purity:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Research Areas:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-16438
CAS No.: 925206-65-1
Synonyms: Nibrozetone
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P1846
CAS No.: 219127-21-6
Target:  

Notch

Research Areas:  

Cancer

Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P1846A
Target:  

Notch

Research Areas:  

Cancer

Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15287
CAS No.: 159989-64-7
Purity:  98.74%
Synonyms: AG1341
Target:  

HIV Protease HIV

Research Areas:  

Infection Cancer

Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15287A
CAS No.: 159989-65-8
Purity:  98.93%
Synonyms: AG 1343 Mesylate
Target:  

HIV Protease HIV

Research Areas:  

Infection Cancer

Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-13241A
CAS No.: 862505-00-8
Synonyms: LY2228820
Target:  

p38 MAPK Autophagy

Research Areas:  

Cancer

Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15888
CAS No.: 315704-66-6
Purity:  99.76%
Target:  

BMI1 Autophagy

Research Areas:  

Cancer

PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment .
loading...
    loading...